Cellectis

Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs.

With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells.

Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).

As a fully integrated leader in genome editing and allogeneic CAR-T cell research, we maintain complete end-to-end control over our manufacturing process.